EHA 2020 – posters

Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients as well as several other posters during EHA. See posters below.

Presentation webcast HORIZON Topline results

Oncopeptides hosted a webcast to present the HORIZON study data and provided a general clinical update March 26, 2020. The webcast was recorded and can be followed via the link: